Adalvo Partners With AmbioPharm For Several Complex Products
Development And Licensing Partnership Includes ‘Difficult-To-Make’ Peptide Products
Alvogen’s newly created B2B unit, Adalvo, has partnered with AmbioPharm for the co-development and licensing for the commercialization of several complex pharmaceutical products, including difficult-to-make peptides, in key global markets.
You may also be interested in...
Upsher-Smith Laboratories, the US arm of Japan’s Sawai Pharmaceutical, has another challenging project in the pipeline with an agreement to develop and market a follow-on version of Mallinckrodt’s Acthar Gel (corticotropin). The Japanese firm revealed Upsher-Smith’s latest finances as it revealed first-quarter financial results.
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
Alvogen’s newly created B2B unit, Adalvo, has filed for a generic version of Takeda’s Firazyr with the EMA to enhace its peptide portfolio, which currently includes several products focused on rare diseases and diabetes. Adalvo believes it is in the first wave of applicants to submit its filing within the European Union.